Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016" report to their offering.

Progressive-relapsing multiple sclerosis (PRMS) refers to a pattern of relapses within primary-progressive MS (PPMS). Signs of PRMS include muscle spasms, weak muscles, dizziness, chronic pain and vision changes. Risk factors include age, family history, autoimmune diseases and smoking. Treatment includes immunosuppressant drugs.

This report provides comprehensive information on the therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Cognosci Inc
  • Genzyme Corp
  • MedImmune LLC
  • VivaCell Biotechnology Espana SL

Key Topics Covered:

  1. Introduction
  2. Progressive Relapsing Multiple Sclerosis (PRMS) Overview
  3. Therapeutics Development
  4. Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview
  5. Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Comparative Analysis
  6. Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies
  7. Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Investigation by Universities/Institutes
  8. Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies
  13. Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Investigation by Universities/Institutes
  14. Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/gzw36l/progressive

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs